Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary pulmonary lymphoma: current status.

Luciano Wannesson1, Franco Cavalli, Emmanuele Zucca

  • 1Department of Medical Oncology, Institute of Southern Switzerland, Bellinzona, Switzerland.

Clinical Lymphoma & Myeloma
|December 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

Blood·2025
Same author

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.

Blood·2025
Same author

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis.

Swiss medical weekly·2024
Same author

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

Haematologica·2024
Same author

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.

International journal of molecular sciences·2024
Same journal

The next generation of therapies for chronic myeloid leukemia.

Clinical lymphoma & myeloma·2009
Same journal

Molecular monitoring of patients with chronic myeloid leukemia: clinical examples from a non-trial setting.

Clinical lymphoma & myeloma·2009
Same journal

Standard management of patients with chronic myeloid leukemia.

Clinical lymphoma & myeloma·2009
Same journal

The chronic myeloid leukemia stem cell.

Clinical lymphoma & myeloma·2009
Same journal

Chronic myeloid leukemia: where do we go now?

Clinical lymphoma & myeloma·2009
Same journal

Bing-Neel syndrome: a case report and systematic review of clinical manifestations, diagnosis, and treatment options.

Clinical lymphoma & myeloma·2009
See all related articles

Primary pulmonary lymphoma (PPL) is a rare lung cancer alternative with a good prognosis. Marginal zone lymphoma is the most common PPL diagnosis, and this review covers its pathology, biology, diagnosis, and treatment.

Area of Science:

  • Pulmonary medicine
  • Hematology
  • Oncology

Background:

  • Primary pulmonary lymphoma (PPL) is a rare neoplastic condition affecting the lungs.
  • It has a more favorable prognosis than primary lung cancer.
  • While various B- and T-cell lymphomas can manifest in the lungs, marginal zone lymphoma (MZL) is the most prevalent subtype.

Purpose of the Study:

  • To provide a comprehensive overview of primary pulmonary lymphoma.
  • To summarize current knowledge on the histopathology, molecular biology, diagnosis, prognosis, and treatment of PPL.
  • To highlight the heterogeneity of this rare entity.

Main Methods:

  • This study is a review of existing literature on primary pulmonary lymphoma.
  • It synthesizes information regarding histopathological classifications.

Related Experiment Videos

  • It also covers molecular findings, diagnostic criteria, prognostic factors, and therapeutic strategies.

    • Main Results:

    • Primary pulmonary lymphoma is a rare condition with a generally favorable outlook.
    • Marginal zone lymphoma of the mucosa-associated lymphoid tissue type is the most frequent histologic diagnosis within PPL.
    • PPL is a heterogeneous group of diseases with diverse characteristics.

    Conclusions:

    • Primary pulmonary lymphoma, particularly MZL, represents a distinct clinical entity with a better prognosis than lung cancer.
    • A thorough understanding of its histopathology, molecular features, and clinical behavior is crucial for accurate diagnosis and effective management.
    • Further research into this heterogeneous group of diseases is warranted to optimize patient outcomes.